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Mapping the medical outcomes study HIV
health survey (MOS-HIV) to the EuroQoL 5
Dimension (EQ-5D-3 L) utility index
Yuan Shi1, Jennifer Thompson2,3, A. Sarah Walker2, Nicholas I. Paton2,4, Yin Bun Cheung5,6* and for the EARNEST
Trial Team
Abstract
Background: Mapping of health-related quality-of-life measures to health utility values can facilitate cost-utility
evaluation. Regression-based methods tend to lead to shrinkage of variance. This study aims to map the Medical
Outcomes Study HIV Health Survey (MOS-HIV) to EuroQoL 5 Dimensions (EQ-5D-3 L) utility index, and to
characterize the performance of three mapping methods, including ordinary least squares (OLS), equi-percentile
method (EPM), and a recently proposed method called Mean Rank Method (MRM).
Methods: This is a secondary analysis of data from a randomized HIV treatment trial. Baseline data from 421
participants were used to develop mapping functions. Follow-up data from 236 participants was used to validate
the mapping functions.
Results: In the training dataset, MRM and OLS, but not EPM, reproduced the observed mean utility (0.731). MRM, OLS
and EPM under-estimated the standard deviation by 0.3, 26.6 and 1.7%, respectively. MRM had the lowest mean
absolute error (0.143) and highest intraclass correlation coefficient (0.723) with the observed utility values, whereas OLS
had the lowest mean squared error (0.038) and highest R-squared (0.542). Regressing the MRM- and OLS-mapped
utility values upon body mass index and log-viral load gave covariate associations comparable to those estimated from
the observed utility data (all P > 0.10). EPM did not achieve this property. Findings from the validation data were similar.
Conclusions: Functions are available for mapping the MOS-HIV to the EQ-5D-3 L utility values. MRM and OLS were
comparable in terms of agreement with the observed utility values at the individual level. MRM had better
performance at the group level in terms of describing the utility distribution.
Trial registration: NCT00988039. Registered 30 September 2009.
Keywords: EQ-5D, Medical outcomes study HIV health survey, Health utility, Mapping
Background
Cost-utility analysis is an important part of the rational
development of health care policy and evaluation of med-
ical interventions. It quantifies the cost required for a gain
in quality-adjusted life years (QALY) [1] The quality
adjustment factor in the estimation of QALY may be
obtained from preference-based measures of patient out-
comes, such as the EuroQoL 5 Dimensions Questionnaire
(EQ-5D) [2] and Health Utilities Index Mark III (HUI3)
[3]. Health state valuation studies have provided algo-
rithms to convert the responses to these measures to
health utility values, where 1 indicates full health, 0 indi-
cates a state that is not better than death, and negative
values indicate health states worse than death [4]. Com-
bining the utility values and patients’ survival duration re-
sult in estimates of QALY, which is needed for cost-utility
analysis. Availability of utility information is a prerequisite
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for QALY and cost-utility analyses, but this information is
not always available.
Clinical studies often employed quality of life measures
that are descriptive, in the sense that they indicate better
or worse quality of life but they do not provide a utility
value that has a quantitative interpretation for adjusting
survival duration to QALY. These descriptive measures
are often conceptually overlapping with preference-based
measures and empirically correlated with the utility values.
In this context, there has been strong interest in develop-
ing functions to map descriptive measures to utility values
using data from prior studies that included both types of
measures [5, 6]. Mapping functions capitalize on descrip-
tive quality of life data and make cost-utility analysis pos-
sible when utility data is otherwise not available. Mapping
is accepted by the National Institute of Health and Care
Excellence Technology Appraisal [7].
Quality of life is an important issue in the care of
people living with human immunodeficiency virus
(HIV). The EuroQoL Group’s 5 Dimensions 3-level instru-
ment (EQ-5D-3 L) is a commonly used preference-based
measure [8]. Its validity and reliability have been demon-
strated in various conditions, including in HIV [9]. The re-
sponses can be converted to health utility values [4]. The
Medical Outcomes Study HIV Health Survey (MOS-HIV)
[10, 11] is a descriptive quality of life measures. Both the
MOS-HIV and EQ-5D covered multiple health dimen-
sions. The MOS-HIV includes 10 dimensions: general
health perceptions, physical functioning, role functioning,
pain, social functioning, mental health, energy, health dis-
tress, cognitive functioning, and quality of life [11]. The
EQ-5D covers five dimensions: mobility, self-care, usual
activities, pain/discomfort and anxiety/depression [4, 8].
Despite the more limited scope of the latter, the two mea-
sures have sufficient overlap for a conceptual basis for
mapping one to the other. A previous study mapped the
MOS-HIV to the EQ-5D-3 L utility index [12]. However,
the study was oriented towards methodological compari-
son about the handling of ceiling effects; the functions
presented used only one or two significant digits, which is
a serious limitation for utility mapping. Availability of
an accurate mapping function can make cost-utility
analysis in HIV studies become possible even when
only MOS-HIV is available.
The ordinary least squares (OLS) is the most com-
monly used method for mapping a descriptive health
measure to a health utility measure [13, 14]. Alternative
regression-based methods have been proposed, but there
has been no consistent evidence that they performed
better than OLS [7, 12, 15–18]. It is well known that
OLS mapping under-estimates variability and therefore
inflates type 1 errors [5]. Furthermore, OLS mapping
tends to under-estimate the health utility of people in
good health states and over-estimate it among people in
bad health states, which leads to under-estimates of the
incremental cost-utility ratio [15, 19–21].
Mapping by the equi-percentile method (EPM) has been
successful and popular in education research [5, 22]. It
does not suffer from the aforementioned problems. There
has been a strong interest in the use of EPM to improve
mapping in the health care context [5, 22]. However, EPM
is usable only if the cumulative distribution functions
(CDF) of the source and target measures are both con-
tinuously increasing. Quality of life and health utility mea-
sures are often discrete in their distributions, giving CDFs
that are step functions. In this situation, Kernel smoothing
is required before EPM can be applied [5]. Smoothing
health utility and patient reported outcome data is not a
simple task. In particular, these measures often have a
substantial ceiling effect, which is known to create extra
difficulties for smoothing [19–21, 23].
A new mapping method called the Mean Rank
Method (MRM) has been recently proposed [21]. Its
core idea is similar to EPM and thus it should have simi-
lar strengths. However, it does not require smoothing
and therefore is much simpler to use than the EPM.
One study has mapped the World Health Organization
Quality of Life – Brief to the EQ-5D-5 L [21] and an-
other study has mapped the Functional Assessment of
Cancer Therapy – Breast (FACT-B) to the EQ-5D-5 L
[20] using MRM. Furthermore, the Alzheimer’s Disease
Cooperative Study-Activities of Daily Living Inventory
(ADCS-ADL) has also been mapped to the Health Util-
ity Index Mark III by the MRM [19]. All three studies
demonstrated good performance properties of the MRM
at the group level. But the MRM did not out-perform
the OLS at the individual level in the FACT-B and
ADCS-ADL studies. Further empirical evaluation of the
properties of MRM will help to improve understanding
of its potentials.
This study therefore aims to map the MOS-HIV to the
EQ-5D-3 L utility index, using MRM, OLS and EPM,
and to examine the performance of the three mapping
functions.
Methods
Study participants and study design
From April 2010 to April 2011, HIV-positive adults
and adolescents over 12 years old from 14 centers in
five sub-Saharan African countries were recruited to
the Europe–Africa Research Network for Evaluation
of Second-Line Therapy (EARNEST) trial. Details of the
trial have been published previously [24]. At weeks 0
(baseline), 48, 96 and 144, the participants completed the
MOS-HIV and EQ-5D-3 L and had their body mass index
(BMI) measured; HIV viral load was also assayed in
real-time at baseline and retrospectively on stored plasma
post-baseline. The MOS-HIV and EQ-5D-3 L were in
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English or in the local languages. To ensure data
consistency, only those who filled in the questionnaire
in English were included in the present analysis. This
secondary analysis was approved by the National Uni-
versity of Singapore Institutional Review Board. The
trial protocol was approved by ethics committees in all
participating countries and by the research ethics commit-
tee of the University College London, UK. All adult partic-
ipants or the caregivers of participants below 18 years of
age provided written informed consent. Patients below 18
years of age also gave assent. Participants were random-
ized to three different drug regimens. This analysis pooled
participants from all trial arms and did not consider the
randomization.
Development and validation datasets
We used data from 421 participants who completed
both MOS-HIV and EQ-5D in English at baseline to de-
velop the mapping functions. Among these 421 partici-
pants, 236 completed both MOS-HIV and EQ-5D-3 L at
one or more of the three scheduled follow-up visits at
week 48, 96 or 144. For each of the 236 participants, we
randomly selected data from one of the follow-up visits
to form a validation dataset, such that it did not involve
multiple measurements per person and hence within
cluster correlation.
Questionnaire
The MOS-HIV consists of 35 items and covers 10 di-
mensions of subjective outcomes [11]. The 10 scores
were converted to z-scores and combined to form a
Physical Health Summary (PHS) score and a Mental
Health Summary (MHS) score that have mean 50 and
standard deviation (SD) 10 [25].
The EQ-5D-3 L measures five aspects of health. There
are three response options for each dimension (no prob-
lem, some problems and extreme problems). The five re-
sponses were converted to a utility value using the
valuation algorithm of Dolan [4].
Mapping methods
Ordinary least squares mapping (OLS)
Multivariable fractional polynomials (FP) were used to
assess the possibility of non-linear relationships between
EQ-5D-3 L utility and PHS and MHS and derive the
mapping function [26]. The deviance difference was used
to guide model selection.
Equi-percentile mapping (EPM)
EPM only allows one predictor variable. We explored
the relationship between EQ-5D-3 L utility and PHS and
MHS using linear regression and FP. A linear regression
model showed that one unit increase in PHS and MHS
was associated with 0.0083 and 0.0117 unit increase in
EQ-5D-3 L utility, respectively. This model explained
52.9% of the variability in the utility values. However, the
difference of the two regression coefficients was not sta-
tistically significant (P = 0.158). Linear regression with a
simple mean of PHS and MHS as an independent variable,
which we called MOS-score in this article, explained
52.6% of the variability in EQ-5D-3 L utility. Given the
similarity in explanatory power, we use the MOS-score to
map the MOS-HIV to EQ-5D-3 L. MOS-score was
rounded to the nearest integer. This rounding enables the
generation of a look-up table for users to apply the map-
ping result (see Online Additional file 1). This practical
purpose was achieved at the expense of generating ties. In
contrast, the OLS mapping result appeared as a prediction
equation that all predicator values, integer or not, can be
plugged into. This issue is addressed in the discussion.
The core concept of the EPM is that the values x and
y are considered equivalent if F(x) = P(X ≤ x) = P(Y ≤ y) =
G(y), where F(x) and G(y) are the cumulative distribu-
tion functions (CDF) of the source variable X and target
variable Y, respectively [5, 21, 22]. However, the EPM
has no solution if the CDFs are step functions, which is
expected in EQ-5D and many quality of life measurement
scales such as WHOQOL-BREF or FACT-B [20, 21].
Hence, kernel smoothing is needed [5, 21, 23]. We used
the Epanechnikov kernel function to smooth the CDFs
[23]. Furthermore, we used the pseudo-data method to
mitigate the boundary effect for EQ-5D [27]. After obtain-
ing the smoothed CDFs, we applied the EPM.
Mean rank method (MRM)
Conceptually, the MRM is similar to the EPM. Instead
of equating the percentiles like EPM, it attempts to
equate the ranks. The MRM mapping procedure is as
follows [21]:
(1) Let X be the predictor variable (MOS-score),
whose values are sorted and ranked from the smallest to
largest. For tied values, mean of ranks is assigned.
(2) Let Y be the target variable (EQ-5D-3 L). Its values
are sorted and ranked from the smallest to the largest.
Among a set of tied values the ranking is arbitrary.
(3) Each unique x value is mapped to the y value that
has the same rank.
(4) For nk tied x values at the k-th level of unique
values in X (k = 1,2,…), x is mapped to the mean of the
nk consecutive y values whose mean of ranks equals the
mean ranks of the tied x values.
Mathematically, the mean MRM-mapped utility
must agree with the mean observed utility [21]. Fur-
thermore, due to the ranking procedure, although
there is no direct modelling of association between X
and Y, rhoðy^MRM; yÞ ¼ rhoðx; yÞ , where y^MRM is the
MRM-mapped value and rho is the Spearman rank
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correlation coefficient, except that ties in Y can cause
some deviation from this relation [21]. This character-
istic is similar to the OLS feature of rðy^OLS; yÞ ¼ rðx; yÞ,
where y^OLS is the OLS-mapped value and r is the Pear-
son’s correlation coefficient. As with EPM, we rounded
the MOS-score to the nearest integer and mapped it
to the EQ-5D-3 L utility by MRM.
Evaluation of mapping functions
Different evaluation criteria may have tendency to favour
different mapping methods. For example, mean squared
errors tends to favour OLS, as minimization of the mean
squared errors is the procedure to obtain the OLS esti-
mates. We used multiple evaluation criteria and attempted
to interpret the overall profile.
Firstly, from the viewpoint of describing a population,
we assessed the mean, SD, and various percentiles of the
mapped utilities and checked whether they closely ap-
proximated that of the observed utility distribution.
Secondly, we calculated measures of individual-level
prediction errors or agreement as compared to the ob-
served EQ-5D-3 L utility values, including mean squared
error (MSE), mean absolute error (MAE), intraclass cor-
relation coefficient (ICC), and R2 in correlating mapped
utility values to the observed. We used the ANOVA esti-
mator of ICC [6].
Thirdly, estimating utility differences between groups
or association with clinical covariates plays a role in
cost-utility analysis [21]. We estimated the linear gradi-
ents of the mapped utilities in relation to either BMI or
log(10)-transformed viral load measured at the time of
completing the MOS-HIV and EQ-5D-5 L and com-
pared the parameter estimates with that obtained from
the observed EQ-5D-3 L utility data. In order to make
the intercepts interpretable, BMI was centered at its
10th percentile and log-viral load was centered at its
90th percentile. As such, the intercepts can be inter-
preted as the estimated mean utility of people living with
HIV in poor health as indicated by low BMI or high viral
load. We used Seemingly Unrelated Regression to test
the hypotheses of equal regression parameters between
each of the mapped utility and the observed utility [28].
Results
Participant profile
The left-hand-side panel of Table 1 shows the baseline
demographic and clinical characteristics of the 421 partici-
pants in the training dataset. The mean age was 37 years;
approximately half (48%) of the participants were male.
Most participants were from Uganda and Zimbabwe.
The mean PHS, MHS, MOS-score and EQ-5D-3 L
utility were 46, 48, 47 and 0.731. The MOS-score
ranged from 18 to 65; the EQ-5D-3 L utility ranged
from − 0.239 to 1. The mapping functions developed
were limited to these ranges. The Pearson’s correl-
ation coefficient between MOS-score and EQ-5D-3 L
utility was 0.725.
The right-hand-side panel of Table 1 shows 236 ob-
servations that formed the validation dataset. The
mean age was 37 years and 56% of the participants
were male. The mean PHS, MHS, MOS-score and
EQ-5D-3 L utility were 56, 57, 57 and 0.936, respect-
ively. The MOS-score ranged from 23 to 65; the
EQ-5D-3 L utility ranged from − 0.163 to 1.
Development of mapping functions and assessment in
the training dataset
OLS mapping
The OLS model selected according to deviance differ-
ence was:
EQ-5D-3 L = − 0.1278036 + 0.0082448 × PHS +
0.0000373 ×MHS3 – (8.43/106) ×MHS3 × ln(MHS).
The model R2 was 54.2%.
MRM and EPM mapping
The MRM and EPM mapping functions that convert the
MOS-score to EQ-5D-3 L utility are provided in Online
Supplementary Material 1 as an electronic spreadsheet.
Comparison of three mapping functions
Figure 1 shows the mean mapped values and the ob-
served utility values. For MOS-scores below about 35,
Table 1 Descriptive summary of demographic and clinical
information and EQ-5D-3 L and MOS-HIV scores in the training
(n = 421) and validation (n = 236) datasets
Variables Training dataset Validation dataset
Mean SD Mean SD
EQ-5D-3 L 0.731 0.290 0.936 0.162
PHSa 46 13 56 9
MHSa 48 10 57 7
MOS-scorea 47 11 57 7
Age 37 11 37 12
CD4 count 101 96 102 96
BMI 21.1 4.4 21.2 4.6
Viral Load (log) 4.8 0.7 4.8 0.6
N % N %
Country Uganda 182 43.2 136 57.6
Zimbabwe 177 42.0 45 19.1
Zambia 36 8.6 31 13.1
Kenya 26 6.2 24 10.2
Gender Male 203 48.2 132 55.9
Female 218 51.8 104 44.1
aPHS Physical Health Summary, MHS Mental Health Summary, MOS-score:
mean of PHS and MHS
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the OLS-mapped utility was higher than the MRM-
mapped utility, and vice versa. The EPM-mapped values
tended to be lower than the OLS- or MRM-mapped values.
The left-hand-side panel of Table 2 shows the details
of the distribution of the observed and mapped EQ-
5D-3 L utilities. The means of both OLS and MRM
agreed closely with the observed value while EPM
under-estimated the mean. The SDs of MRM and EPM
were similar to the SD of the observed utility values,
while OLS under-estimated the SD by 27%. The 75th per-
centile of the observed EQ-5D-3 L utility reached the full
health utility of 1, so did MRM. The maximum of the
OLS- and EPM-mapped values were 0.996 and 0.992, re-
spectively. The MRM gave 5th, 10th and 25th percentiles
similar to the observed, with absolute errors smaller than
0.02. OLS over-estimated all three percentiles, with errors
ranging from 0.058 (25th percentile) to 0.234 (5th per-
centile). The EPM gave absolute errors ranging from 0.028
(10th percentile) and 0.080 (25th percentile).
The left-hand-side panel of Table 3 shows the mea-
sures of (dis)agreement between the mapped and ob-
served utilities at the individual level. MRM gave smaller
Fig. 1 Observed EQ-5D-3 L utility values and mean mapped values obtained from the mean rank method (MRM), equi-percentile method (EPM)
and ordinary least square (OLS) in the 18 to 65 range of MOS-score. (With random jittering to avoid over-lapping of data points)
Table 2 Distribution of observed and mapped EQ-5D utility values in the training (N = 421) and validation (N = 236) datasets
Statisticsa Training dataset Validation dataset
Observed MRM OLS EPM Observed MRM OLS EPM
Mean 0.731 0.731 0.731 0.668 0.936 0.932 0.896 0.874
SD 0.290 0.289 0.213 0.285 0.162 0.149 0.121 0.153
Minimum −0.239 −0.239 0.088 −0.322 − 0.163 − 0.074 0.226 − 0.123
P5 0.088 0.070 0.322 0.029 0.516 0.678 0.622 0.601
P10 0.228 0.246 0.401 0.200 0.796 0.726 0.713 0.699
P25 0.656 0.645 0.598 0.576 1.000 0.918 0.888 0.837
Median 0.796 0.796 0.771 0.745 1.000 1.000 0.946 0.933
P75 1.000 1.000 0.917 0.876 1.000 1.000 0.964 0.962
P90 1.000 1.000 0.959 0.95 1.000 1.000 0.971 0.983
P95 1.000 1.000 0.969 0.962 1.000 1.000 0.978 0.989
Maximum 1.000 1.000 0.996 0.992 1.000 1.000 0.997 0.992
aP Percentile
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mean absolute error and higher intraclass correlation
coefficient than the other two methods did. OLS gave
smaller mean squared error and higher R2 than the
other two methods did.
The left-hand-side panel of Table 4 shows the associa-
tions between utilities and BMI and viral load from the
regression models. The observed EQ-5D-3 L utility in
relation to baseline BMI had an intercept of 0.681 and a
slope of 0.009. MRM- and OLS-mapped EQ-5D-3 L util-
ities showed similar patterns as compared to the observed
EQ-5D-3 L’s (model P = 0.690 and 0.881, respectively). In
contrast, the EPM under-estimated the intercept although
the estimated slope was similar to that of the observed
EQ-5D-3 L’s (model P < 0.001). Analysis of observed and
mapped-utility in relation to log-viral load gave similar
findings that MRM and OLS produced association pattern
comparable to that of the observed EQ-5D-3 L, but EPM
did not (P < 0.001).
Validation
The right-hand-side panels of Tables 2, 3 and 4 show the
results in the analysis of the validation dataset. They
mostly agreed with the patterns seen in the training
dataset. A difference between the training and validation
was that the OLS did not agree with the observed utility
pattern in relation to BMI and log-viral load in the valid-
ation dataset (right-hand-side of Table 4), despite its
agreement in the training dataset. In particular, it
under-estimated the intercept in relation to both BMI
and log-viral load (each P < 0.05 for the intercept; each
P ≤ 0.001 for the model).
Discussion
We employed the OLS, EPM and the recently proposed
MRM to map the MOS-HIV quality of life scores to
EQ-5D-3 L utilities. The OLS is the most commonly
used method in the health care context so far [13, 14],
but it suffers shrinkage of variance and inaccurate esti-
mation in relation to covariates [5, 15, 21]. There are
other regression-based methods, such as the Tobit re-
gression and indirect mapping by multinomial logistic
regression [7, 18]. These regression methods do not con-
sistently perform better than the OLS [7, 17, 19].
The applicability of the EPM in the health care context
has received a lot of attention. But actual implementa-
tion of it has been limited in health research. Two re-
views in this field recorded no mapping study that used
EPM [13, 14]. This may be related to the nature of CDFs
of health utility and descriptive health measures often
being step functions, sometimes with a sizeable mass at
the ceiling, which makes EPM difficult to implement.
The MRM overcomes this complexity by equating mean
ranks to handle tied values, instead of smoothing.
One relative strength of OLS is that, unlike the MRM
and EPM, it can use multiple predictor variables. In the
present study, we used both the PHS and MHS instead
of an overall summary score as the OLS predictors. In
contrast, we used the mean of PHS and MHS to gener-
ate a single predictor variable as the input for MRM and
EPM. In this regard, the accuracy of the mapping func-
tions derived may be affected by two factors. Firstly, the
association between the observed utilities and PHS and
MHS should be approximately equal. As shown earlier,
Table 3 Mean squared errors (MSE), mean absolute errors
(MAE), intraclass correlation coefficient (ICC) and R-squared (R2)
of the Mean Rank-, OLS- and Equipercentile-mapped EQ-5D-3 L
utilities as compared to the observed EQ-5D-3 L utilities in the
training (N = 421) and validation (N = 236) datasets
Method Training dataset Validation dataset
MSE MAE ICC R2 MSE MAE ICC R2
MRM 0.046 0.143 0.723 0.522 0.019 0.068 0.600 0.361
OLS 0.038 0.147 0.703 0.542 0.019 0.094 0.544 0.356
EPM 0.049 0.158 0.707 0.528 0.023 0.106 0.553 0.376
Table 4 Relation between observed and mapped EQ-5D-3 L utilities and body mass index and log-transformed viral load in training
(n = 421) and validation (n = 236) datasets
Clinical Methods Training dataset Validation dataset
feature Intercept P Slope P Model P Intercept P Slope P Model P
BMI Observed 0.681 Ref. 0.009 Ref. Ref. 0.913 Ref. 0.003 Ref. Ref.
MRM 0.669 0.491 0.011 0.390 0.690 0.909 0.800 0.003 0.959 0.950
OLS 0.686 0.720 0.008 0.615 0.881 0.879 0.014 0.002 0.724 < 0.001
EPM 0.610 < 0.001 0.011 0.525 < 0.001 0.853 < 0.001 0.003 0.995 < 0.001
Viral load Observed 0.683 Ref. −0.024 Ref. Ref. 0.935 Ref. 0.002 Ref. Ref.
MRM 0.675 0.625 −0.028 0.534 0.824 0.921 0.507 −0.004 0.491 0.783
OLS 0.687 0.796 −0.022 0.742 0.947 0.891 0.027 −0.002 0.631 0.001
EPM 0.613 < 0.001 −0.028 0.537 < 0.001 0.866 0.001 −0.002 0.589 < 0.001
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we assessed the equality and found this condition plaus-
ible. Secondly, a large deviation of the PHS/MHS ratio
from unity (one) may exacerbate the impact of the afore-
mentioned difference, if any. As shown in Table 1, the
mean PHS and MHS scores were similar in this study.
The mean PHS/MHS ratio was 0.97 in the training data-
set. The number of participants who had PHS/MHS ra-
tio < 0.7 or > 1.3 were 40 and 24, respectively. With such
small sub-group sample sizes, we refrained from further
analyses by sub-groups. While the MRM-derived
MOS-HIV to EQ-5D utility mapping function per-
formed well in this study, its performance in other popu-
lations will need further assessment in relation to the
two conditions aforementioned. Another potential rela-
tive strength of the OLS is that the application of an
OLS mapping formula does not require rounding of the
predictor scores. Unlike many other patient reported
outcomes like WHOQOL-BREF or FACT-B which gen-
erate integer values, the weighted average procedure in
MOS-HIV generates non-integers. For easy utilization of
the MRM and EPM mapping results, we rounded the
predictor values to integers so that the results can be
presented as a simple look-up table. Nevertheless, in this
study the OLS did not perform better than the MRM. A
previous simulation study has shown that the MRM had
mean absolute errors smaller than or equal to OLS even
if predictor scores were coarsened to only 10 levels [21].
As such, we expected the rounding to integers to have
minimal impact on the accuracy of MRM. Our findings
on EPM in this study refer to EPM as applied with
MOS-HIV scores rounded to integers.
We have reservations about including demographic
and clinical variables in mapping, a practice that has
been seen in the health and quality of life literature. This
practice changes the research purpose from “mapping a
descriptive health measure to a utility measure” to “map-
ping multiple measures to a utility measure”. The impli-
cation of the practice is that the mapping function is not
usable unless all the demographic and clinical variables
involved in the mapping algorithm are also available.
In the present study, MRM generated a utility distri-
bution that closely reflected the features of the ob-
served utility distribution, including the mean, SD,
various percentiles, and the level of ceiling effect. The
OLS accurately reproduced the observed mean utility
values in the training dataset but under-estimated the
mean in the validation dataset. Neither OLS nor EPM
were accurate in describing the variability and percen-
tiles at the lower and upper ends of the utility
distribution.
As expected, in the training dataset the mean squared
error was lowest in the OLS-based mapping. However,
in the training dataset both the OLS and EPM had
higher mean absolute errors and lower ICC than the
MRM. Furthermore, in the validation dataset, the MRM
had the same mean squared error as the OLS and better
performance according to all other indicators. There was
no strong and consistent pattern to indicate whether OLS
or MRM was more accurate in making individual-level
predictions, but EPM was consistently inferior.
MRM agreed with the observed data in reproducing
observed association patterns with clinical covariates.
OLS agreed with the observed data in the training
dataset but not in the validation dataset. The EPM
performed worst in this regard. This suggests that
OLS and EPM mapping are less suitable for studies
that wish to explore associations. Our study supports
the use of MRM, but further validation of this is
required.
The mapped values all showed a reasonable degree of
accuracy in terms of R2 over 0.5 in the training dataset.
This is comparable to a review of mapping studies which
showed the R2 in the training datasets in the mapping of
disease-specific health measures to utility indices was
typically less than 0.5, while mapping of generic health
measures typically had within training dataset R2 in the
range of 0.4 to 0.6 [13].
We acknowledge that this study has several limita-
tions. Firstly, the MOS-score in the trial only covered
the 18 to 65 range. Based on the MOS-HIV reference
data [25], the mean and SD are 50 and 10, respect-
ively. The present study covers the lower range quite
well (to about − 3 SD) but not the upper range (to
about 1.5 SD). This may limit the applicability of the
mapping in populations with good health and quality
of life. Secondly, the study included only people living
with HIV in four African countries. The applicability
of the mapping functions in other populations need
further evaluation. This includes further evaluation of
the relative strength of the association between EQ-5D
utilities and PHS and MHS in other populations and
the mapping functions’ performance in populations
that have PHS/MHS ratio substantially different from
unity. Thirdly, the study used the 3-level EQ-5D in-
stead of the latest 5-level EQ-5D (EQ-5D-5 L). Cur-
rently there is no official valuation set for mapping the
responses to the EQ-5D-5 L to a utility index. Until
this is developed, the mapped or observed EQ-5D-3 L
utilities will remain useful. In the longer term, updat-
ing of the mapping using the EQ-5D-5 L will be
needed. Fourthly, our validation dataset was not a ran-
domly selected sample independent of the training
dataset, this could have increased the similarity of the
training and validation results. However, this impact
was minor in this data, because the correlation be-
tween EQ-5D-3 L utility at baseline and subsequent
visits was weak, ranging from 0.18 (with week 144) to
0.25 (with week 48).
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Conclusions
The MRM performed well in most regards. This method
can contribute to future mapping studies. A table for the
conversion of MOS-HIV scores to EQ-5D-3 L utility
index is provided. This can facilitate cost-utility analysis
in the care of people living with HIV.
Additional file
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